Regenxbio公司发布了其治疗黏多糖贮积症II型(MPS II)药物RGX-121的CAMPSIITE® I/II/III期临床试验12个月关键数据,结果显示积极疗效。
Regenxbio公司发布了其治疗黏多糖贮积症II型(MPS II)药物RGX-121的CAMPSIITE® I/II/III期临床试验12个月关键数据,结果显示积极疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.